Nature - Lifetime of plasma cells in the bone marrow

(NaturalHealth365) An unprecedented number of athletes have suffered cardiac issues in 2020. Could the COVID shot program be to blame?

Nature - Clinical evidence for long-lasting immunity to SARS-CoV-2 infection

Nature - SARS-CoV-2 infection induces long-lived bone marrow plasma cells that correlate with anti-SARS-CoV-2 spike protein antibody titres in individuals who have recovered from COVID-19.

The ivermectin docking we identified may interfere with the attachment of the spike to the human cell membrane. Clinical trials now underway should determine whether ivermectin is an effective treatment for SARS-Cov2 infection.

Nopal (Opuntia ficus indica) belonging to the Cactacea family has many nutritional benefits attributed to a wide variety of phenolic and flavonoid compounds. Coumaric acid (COA), ferulic acid (FLA), protocatechuic acid (PRA), and gallic acid (GAA) are the phenolic acids (PhAs) present in nopal. In this study, the role of these PhAs in copper-induced oxidative stress was investigated using the density functional theory (DFT). The PhAs form 5 thermodynamically favorable complexes with Cu(II), their conditional Gibbs free energies of reaction (ΔG’, at pH = 7.4, in kcal/mol) are from −23 kcal/mol to −18 kcal/mol. All of them are bi-dentate complexes. The complexes of PRA and GAA are capable of inhibiting the Cu(II) reduction by both O2•− and Asc−, their reactions with the chelated metal are endergonic having rate constants about ~10−5–102 M−1 s−1, PhAs can prevent the formation of hydroxyl free radicals by chelating the copper ions. Once the hydroxyl radicals are formed by Fenton reactions, the complexes of PhAs with Cu(II) can immediately react with them, thus inhibiting the damage that they can cause to molecules of biological interest. The reactions between PhAs-Cu(II) complexes and hydroxyl free radical were estimated to be diffusion-limited (~108 M−1s−1). Thus, these chelates can reduce the harmful effects caused by the most reactive free radical existent immediately after it is formed by Fenton reactions.

Her scientific conclusions about the COVID-19 pandemic and the origins of the CCP (Chinese Communist Party) virus are ...

In this interview with internationally renowned Dr. Shankara Chetty from South Africa, we discuss the Omicron variant, which is taking the world as a storm. Is this variant to be feared, or could it actually be a positive development in this pandemic, as mostly inducing mild disease, yet conferring post-covid natural immunity. These are among the timely and critically important aspects we discuss. Dr. Chetty is a Family General Medical Practitioner in South-Africa, with considerable experience with the outpatient treatment of COVID-19, having treated so far nearly 8,000 patients, in his outpatient practice, without any of them requiring hospitalization or even oxygen. Dr. Chetty holds a degree in medicine and surgery and also has advanced education in genetics, advanced biology, biochemistry and microbiology. More interviews: https://covexit.com/category/videos/

This is an evolving guide with emerging information on how to clear viral and vaccine-induced spike proteins from the body.

A New York-based, multi-institutional research team has found high levels of three toxic metabolites produced by gut bacteria in the cerebrospinal fluid and plasma samples of multiple sclerosis (MS) patients. The important findings further scientists' understanding of how gut bacteria can impact the course of neurological diseases by producing compounds that are toxic to nerve cells.

Let’s unpack a unique compilation of supplements and explore not just the value of each component and how they work synergistically to lower uric acid.

The recent COVID-19 pandemic is a treatment challenge in the acute infection stage but the recognition of chronic COVID-19 symptoms termed post-acute sequelae SARS-CoV-2 infection (PASC) may affect up to 30% of all infected individuals. The underlying mechanism and source of this distinct immunologic condition three months or more after initial infection remains elusive. Here, we investigated the presence of SARS-CoV-2 S1 protein in 46 individuals. We analyzed T-cell, B-cell, and monocytic subsets in both severe COVID-19 patients and in patients with post-acute sequelae of COVID-19 (PASC). The levels of both intermediate (CD14+, CD16+) and non-classical monocyte (CD14Lo, CD16+) were significantly elevated in PASC patients up to 15 months post-acute infection compared to healthy controls (P=0.002 and P=0.01, respectively). A statistically significant number of non-classical monocytes contained SARS-CoV-2 S1 protein in both severe (P=0.004) and PASC patients (P=0.02) out to 15 months post-infection. Non-classical monocytes were sorted from PASC patients using flow cytometric sorting and the SARS-CoV-2 S1 protein was confirmed by mass spectrometry. Cells from 4 out of 11 severe COVID-19 patients and 1 out of 26 also contained SARS-CoV-2 RNA. Non-classical monocytes are capable of causing inflammation throughout the body in response to fractalkine/CX3CL1 and RANTES/CCR5. Summary SARS CoV-2 S1 Protein in CD16+ Monocytes In PASC ### Competing Interest Statement B.K.P, A.P., H.R., E.L, and EBF. are employees of IncellDx

Nature - People who recover from mild COVID-19 have bone-marrow cells that can churn out antibodies for decades, although viral variants could dampen some of the protection they offer.

Investigation and Prosecution of Those Individuals Responsible for Crimes Against Humanity   29 September 2021     The International Criminal Court Office of the Prosecutor Post Office Box 19519 2500 CM The Hague The Netherlands     And   Ms. Karen Mosoti, or official replacement for the office of Liaison Office of the International Criminal Court to the United Nations 866 United Nations Plaza Suite 476 New York, NY, 10017 USA 212-486-1346/47/62     Email: otp.informationdesk@icc-cpi.int   Dear

By Dr. Mike Williams21stcenturywire.com In prior articles we discussed the increased risk of SARS-COV-2 infection after Covid vaccination and introduced concepts of immune tolerance and immune training. In this article I want to introduce the topic of cellular senescence, specifically as it relates to Covid vaccination. From Cellular Senescence: What, Why, and How we learn: Cellular senescence is a process […]

e-Sword is a feature rich and user friendly free Windows app with everything needed to study the Bible in an enjoyable and enriching manner!

(NaturalHealth365) New Swedish study raises red flags about COVID jab deaths, shows people dying at alarming rates.

(NaturalHealth365) Headline of a recently published Forbes article claiming that mRNA injections alter human DNA triggers massive backlash.

Methods: Open-label, multicenter, retrospective, noncontrolled analysis of long-term visual acuity and safety in 111 LHON patients treated with idebenone (900 mg/day) in an expanded access program. Eligible patients had a confirmed mitochondrial DNA mutation and had experienced the onset of symptoms (most recent eye) within 1 year before enrollment. Data on visual acuity and adverse events were collected as per normal clinical practice. Efficacy was assessed as the proportion of patients with either a clinically relevant recovery (CRR) or a clinically relevant stabilization (CRS) of visual acuity. In the case of CRR, time to and magnitude of recovery over the course of time were also assessed. Results: At time of analysis, 87 patients had provided longitudinal efficacy data. Average treatment duration was 25.6 months. CRR was observed in 46.0% of patients. Analysis of treatment effect by duration showed that the proportion of patients with recovery and the magnitude of recovery increased with treatment duration. Average gain in best-corrected visual acuity for responders was 0.72 logarithm of the minimal angle of resolution (logMAR), equivalent to more than 7 lines on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Furthermore, 50% of patients who had a visual acuity below 1.0 logMAR in at least one eye at initiation of treatment successfully maintained their vision below this threshold by last observation. Idebenone was well tolerated, with most adverse events classified as minor. Conclusions: These data demonstrate the benefit of idebenone treatment in recovering lost vision and maintaining good residual vision in a real-world setting. Together, these findings indicate that idebenone treatment should be initiated early and be maintained more than 24 months to maximize efficacy. Safety results were consistent with the known safety profile of idebenone....

David Martin specialises in putting humanity back into humans - and business. David's secret of success globally is ‘The Wobble Effect’. Read more...

Click here to download the document as a PDF

welcome everyone we love you!